Pfizer's First GLP-1 Innovative Drug, Xianweiying® (Enoglutide Injection), Launches Presales on Meituan Maoyao

On April 16, Pfizer’s First GLP-1 Receptor Agonist, Xianweiyin^®(Generic Name: Enoglutide Injection) has officially launched on the Meituan Medicine platform, initiating online medication search and appointment services. This marks another innovative weight-loss drug, following semaglutide and tirzepatide, to prioritize consumer access through online appointment platforms.

As an innovative cAMP-biased GLP-1 receptor agonist, Xianweiying^®A significant breakthrough has been achieved in the drug’s mechanism of action. Its unique biased signaling mechanism effectively activates the GLP-1 receptor pathway, delivering potent weight-loss effects while demonstrating favorable gastrointestinal tolerability. According to Phase III clinical trial data published in The Lancet Diabetes & Endocrinology, participants achieved a mean weight reduction of 15.4% after 48 weeks of continuous treatment. Notably, only 0.6% of patients discontinued treatment due to gastrointestinal adverse events. Patients experienced sustained weight loss throughout the treatment period, with no plateau phase observed.

Now, by searching for the keyword “Xianweiying” on the Meituan app, consumers can directly view information on nearby institutions and the corresponding prices for medication reservation services. Industry insiders note that the Meituan Medicine platform boasts a large base of active users, with search interest in weight-loss medications remaining consistently high. By integrating online search and consultation, patient education and science popularization, and offline medical institutions, the platform enables more patients in need to promptly locate medications and receive convenient, professional support for their medication use.

In recent years, innovative drugs represented by GLP-1 agents have been undergoing a structural shift from “high-priced and niche” to “affordable and accessible,” with market demand accelerating. Data shows that since March this year, multiple glucose-lowering and weight-loss medications have consistently ranked among the top ten most-searched items on Meituan Medicine’s hot search list. Amid this trend, Meituan Medicine has gradually become a core platform for the online launch of innovative weight-loss drugs from both domestic and international manufacturers. Since last year, Novo Nordisk’s^®, Mufenda^®, Xin'ermei^®Multiple innovative glucose-lowering and weight-loss drugs have successively made their online debut on Meituan.